Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37,884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: song y. Anticancer Res. 2024 Aug;44(8):3409-3417. doi: 10.21873/anticanres.17161. Anticancer Res. 2024. PMID: 39060060
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: song y. Cancer Manag Res. 2021 Oct 24;13:8049-8056. doi: 10.2147/CMAR.S333823. eCollection 2021. Cancer Manag Res. 2021. PMID: 34729023 Free PMC article.
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Miura A, Komori H, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: song y. Cancer Manag Res. 2022 May 3;14:1641-1651. doi: 10.2147/CMAR.S360473. eCollection 2022. Cancer Manag Res. 2022. PMID: 35535266 Free PMC article.
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Kobayashi H, Wada Y, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: song y. Onco Targets Ther. 2022 Nov 5;15:1321-1330. doi: 10.2147/OTT.S389138. eCollection 2022. Onco Targets Ther. 2022. PMID: 36388155 Free PMC article.
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Masaoka H, Harada M, Tamura S, Kobayashi H, Morihara K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: song y. Anticancer Res. 2023 Oct;43(10):4701-4708. doi: 10.21873/anticanres.16666. Anticancer Res. 2023. PMID: 37772560
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: song y. Curr Oncol. 2024 Feb 3;31(2):862-871. doi: 10.3390/curroncol31020064. Curr Oncol. 2024. PMID: 38392058 Free PMC article.
Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: song y. Anticancer Res. 2024 Jul;44(7):3025-3032. doi: 10.21873/anticanres.17115. Anticancer Res. 2024. PMID: 38925809
Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: song y. Clin Genitourin Cancer. 2024 Oct;22(5):102148. doi: 10.1016/j.clgc.2024.102148. Epub 2024 Jul 2. Clin Genitourin Cancer. 2024. PMID: 39033710 Free article.
37,884 results
You have reached the last available page of results. Please see the User Guide for more information.